Aug 2026· Cancers· Vol 18, pp. 2741· 0 citations· 43 references
Medicine
TL;DR
How fertility-sparing treatment has expanded from oral progestin therapy alone to include local intrauterine therapy, hysteroscopic lesion resection, metabolic interventions, combined endocrine therapy, and selected molecularly guided strategies is described.
Abstract
Simple Summary Endometrial cancer is increasingly affecting individuals who have not yet completed childbearing. For carefully selected patients with early-stage, low-risk disease, fertility-sparing treatment can preserve the uterus while the disease is closely monitored. However, responses to conventional progestin therapy vary, particularly among patients with obesity, polycystic ovary syndrome, abnormal glucose metabolism, Lynch syndrome, mismatch repair-deficient tumors, persistent disease, or recurrent disease. This review describes how fertility-sparing treatment has expanded from oral progestin therapy alone to include local intrauterine therapy, hysteroscopic lesion resection, metabolic interventions, combined endocrine therapy, and selected molecularly guided strategies. It also summarizes the patient populations most likely to benefit from each approach, their limitations, and the circumstances in which fertility-sparing treatment should be discontinued. Integrating pathological, metabolic, molecular, treatment-response, and reproductive factors may help clinicians better balance oncologic safety with the opportunity for future pregnancy.
Current evidence suggests that NSMP tumors represent the most favorable subgroup for FST, showing the highest complete response rates and lowest recurrence rates, likely due to preserved estrogen and progesterone receptor signaling.
F. Ferrari, G. Bogani, M. Pavone et al.· Frontiers in Oncology· 0 citations
BACKGROUND
Molecular profiling has transformed endometrial carcinoma management, yet its value in predicting response to fertility-sparing conservative treatment remains undefined.
OBJECTIVE
To provide pooled estimates of oncologic outcomes of fertility-sparing treatment in women with early-stage endometrioid endomet...
A. Raffone, D. Neola, Angelica Tranchini et al.· Gynecologic Oncology· 0 citations
It is concluded that POI management must be individualized and multidisciplinary, based on an assessment of systemic risks, etiology, age, residual follicular activity, and the patient's reproductive goals.
Caren Andrigheti Grazziotin, Beatriz Donatelli Moro, Natália Passos Torres de Araújo et al.· International Journal of Hea...· 0 citations
Background Lynch syndrome-associated endometrial cancer (LS-EC) presents unique challenges for fertility preservation. Conventional progestin-based therapy may be less effective in mismatch repair-deficient (MMRd) tumors, whereas immune checkpoint inhibitors (ICIs) have shown promising activity. Meanwhile, preimplantat...
Yan-Nan Zhao, Yue Zhao, Ting Hu et al.· Frontiers in Oncology· 0 citations
Breast cancer is the most common malignancy in reproductive-age women, and its incidence is rising fastest in those under 50 as early-stage survival exceeds 90%. This review synthesizes current evidence on fertility preservation in breast cancer, focusing on the safety, efficacy, and available options. Early referral f...
Samantha McLean, A. Herweck, M. Pavone· Current Breast Cancer Report...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.